MaxCyte Stock

MaxCyte EBITDA per Share

The EBITDA per Share of MaxCyte (MXCT) as of Sep 5, 2026 is -0.45 USD. In the previous year, EBITDA per Share was -0.43 USD — a change of 4.58% (lower).

EBITDA per Share

-0.45USD

YoY

4.58%

Last updated:

EBITDA per Share of MaxCyte is 2026 -0.45 USD. EBITDA per Share of MaxCyte was 2025 -0.43 USD. It decreases by 4.58% lower compared to the previous year.

The MaxCyte EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2017
-0.19 USD
Jan 1, 2018
-0.16 USD
Jan 1, 2019
-0.22 USD
Jan 1, 2020
-0.16 USD
Jan 1, 2021
-0.19 USD
Jan 1, 2022
-0.24 USD
Jan 1, 2023
-0.43 USD
Jan 1, 2024
-0.45 USD
The MaxCyte EBITDA per Share history
YEAREBITDA per ShareYoY
-0.45USD+4.58%
-0.43USD+75.76%
-0.24USD+31.38%
-0.19USD+16.71%
-0.16USD-27.69%
-0.22USD+33.85%
-0.16USD-13.86%
-0.19USD+135.37%
-0.08USD+364.13%
-0.02USD-40.63%
-0.03USD—
Access this data via the Eulerpool API
Get Free API Key

MaxCyte Stock analysis

What does MaxCyte do? MaxCyte Inc is a US biotechnology company specializing in the development of platform-based technologies for the next generation of gene and cell therapies. They offer integrated platform technology for drug manufacturing, research, and development. Their proprietary platform technology, Flow ElectroporationTM, allows for efficient transduction of a variety of cells, making it a valuable tool for the production of CAR-T cell therapies. They also offer services for lentiviral production and customized gene therapy production. MaxCyte has secured $50 million in funding for expansion and has formed important partnerships in the industry. They are a leading player in the development of innovative technologies for gene and cell therapy products. MaxCyte is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MaxCyte stock

EBITDA per Share of MaxCyte is -0.45 USD in 2026.

EBITDA per Share of MaxCyte changed from -0.43 USD to -0.45 USD, representing a 4.58% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share MaxCyte since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API
Get Free API Key

Income Statement — MaxCyte

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — MaxCyte